Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by MirrorWorldManon Nov 30, 2020 2:27pm
128 Views
Post# 32001997

RE:RE:Solid Update

RE:RE:Solid UpdateMy feeling is his China efforts will fail (yet again) as Howie realizes (again) that he steered by a Chinese carrot pulling a cart of Chinese promises between a never ending group of shallow Chinese companies.  Is he really trying to educate us pre-shoolers on why there are delays?  Maybe he  is the one that needs to back to school...

Is he preparing us for some kind of super conglomerate of partners buuble in China that will take our little molecule from approval to commercialization rather than  put the pieces together himself.  This approach will again fail over the next 2 years (see carrot). 

He walked away from China once before, citing the difficulties of doing business, threatened to go it alone,  then suddenly waived some paper around and said he is excited to return to China with new deals/.  Now he  said those deals are not good and we are looking for new partners.  He should prescribe himeself some bipolar meds...

We have a manufacturing facility to produce something that is not even approved for use?   We dont even have approval from CFDA to promote 1067 yet.  Good luck with that Howie.   

China is out of the equation for me and Howie insists all is fine and he is in control of the direction and is happy to report the news in a shareholder update,  The launch of 1067 is not part of his list of 7 month milestones, hence will not occur in the immediate future.  So much is misleading and so little delivered. 

Its a miracle this guy is still on the board, he would of been fired long ago by any other reputable firm.
<< Previous
Bullboard Posts
Next >>